| Abstrakt: |
A study conducted by the University of California San Francisco (UCSF) examined the feasibility of using Gastrografin, a water-soluble contrast agent, for the management of adhesive small bowel obstruction (SBO) in low-income countries. The study found that the use of Gastrografin can predict nonoperative resolution of SBO and reduce decision time to surgery and length of hospital stay. However, the study also highlighted challenges in implementing this protocol in low-income settings. The research suggests that further studies are needed to determine the effectiveness of Gastrografin use in Ethiopia and other low-income and middle-income countries. [Extracted from the article] |
